Giant cell tumor of bone: treatment and outcome of 214 cases
- 692 Downloads
Two hundred and fourteen patients with benign giant cell tumor of bone (GCTB), treated from 1980 to 2007 at the Department of Orthopedics of the University of Muenster (Germany), were analyzed in a retrospective study.
Patients and methods
The mean age was 33.3 years with a female-to-male ratio of 1.2 : 1. The mean follow up was 59.8 months. The recurrence rate of patients who received first treatment at our institution was 16.6%. The most common primary treatment was curettage (188 patients) usually followed by adjuvant local therapy. The effects of bone cement (PMMA), burring and hydrogen peroxide (H2O2) were statistically analyzed and the influence of a subchondral bone graft on the recurrence rate was evaluated.
PMMA alone (n = 52) reduces the likelihood of recurrence by the factor 8.2, additional high-speed burring (n = 39) by the factor 3.9 (compared to PMMA only). H2O2 (n = 42) seems to have an additional effect comparable to that of phenol although it did not reach statistical significance.
The combination of all adjuncts (PMMA, burring, H2O2 − n = 42) reduces the likelihood of recurrence by the factor 28.2 compared to curettage only and therefore should be recommended as a standard treatment. If the tumor reaches close to the articulating surface a subchondral bone graft (n = 42) can be performed without risking a higher recurrence rate. We add seven cases of pulmonary metastases and two cases of multicentricity to the literature. Bisphosphonates and interferon alpha may have a beneficial effect.
KeywordsGiant cell tumor of bone Bone neoplasm Local recurrence Hydrogen peroxide Bone cement Curettage Pulmonary metastases
Conflict of interest statement
Each author certifies that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article.
- Campanacci M (1990) Bone and soft tissue tumors. Springer, New York, pp 117–151Google Scholar
- Campanacci M (1994) Giant-cell tumor and chondrosarcoma: grading, treatment and results. Recent Results Cancer Res 999:257–261Google Scholar
- Enneking WF (1983) Staging of musculoskeletal tumors. In: Enneking WF (ed) Musculoskeletal tumor surgery, vol 1. Churchill Livingstone, New York, pp 87–88Google Scholar
- Fan Q, Ma B, Guo A, Li Y, Ye J, Zhou Y, Qiu X (1996) Surgical treatment of bone tumors in conjunction with microwave-induced hyperthermia and adjuvant immunotherapy. A preliminary report. Chin Med J (Engl) 109(6):425–431Google Scholar
- Freyschmidt J, Ostertag H, Jundt G (1998) Knochentumoren. 2. Auflage. Springer, Berlin, pp 611–649Google Scholar
- Jaffe HL, Lichtenstein L, Portis RB (1940) Giant cell tumor of bone. Its pathologic appearance, grading, supposed variants and treatment. Arch Pathol 30:993–1031Google Scholar
- Punyaratabandhu T, Srisawat P, Charoenvareekul S, Songpatanasilp T, Khunkitti N, Pipithkul S (2007) The effect of intravenous bishosphonate on giant cell tumor of bone: Preliminary report. ISOLS P 2.31Google Scholar
- Sanjay BK, Younge DA (1996) Giant cell tumour of metacarpal with pulmonary and skeletal metastases. J Hand Surg [Br] 21(1):126–132Google Scholar
- Schwartz HS (1998) Update on giant cell tumor of bone. Comp Ther 24(10):488–493Google Scholar
- Stewart DJ, Belanger R, Benjamin RS (1995) Prolonged disease-free survival following surgical debulking and high-dose cisplatin/doxorubicin in a patient with bulky metastases from giant cell tumor of bone refractory to “standard” chemotherapy. Am J Clin Oncol 18(2):144–148PubMedCrossRefGoogle Scholar
- Vult von Steyern F, Bauer HC, Trovik C, Kivioja A, Bergh P, Holmberg Jorgensen P, Folleras G, Rydholm A (2006) Treatment of local recurrences of giant cell tumour in long bones after curettage and cementing. A Scandinavian Sarcoma Group study. J Bone Joint Surg Br 88(4):531–535CrossRefGoogle Scholar